Literature DB >> 23185284

Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of hepatocellular carcinoma.

Kang Song1, Jiayong Yi, Xizhong Shen, Yu Cai.   

Abstract

BACKGROUND: A number of case-control studies were conducted to investigate the association of glutathione S-transferase (GST) genetic polymorphisms and hepatocellular carcinoma (HCC) risk. However, these studies have yielded contradictory results. We therefore performed a meta-analysis to derive a more precise estimation of the association between polymorphisms on GSTM1, GSTT1 and HCC. METHODOLOGY/PRINICPAL
FINDINGS: PubMed, EMBASE, ISI web of science and the CNKI databases were systematically searched to identify relevant studies. Data were abstracted independently by two reviewers. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to assess the strength of association. Potential sources of heterogeneity were also assessed by subgroup analysis and meta-regression. Funnel plots and Egger's linear regression were used to test publication bias among the articles. A total of 34 studies including 4,463 cases and 6,857 controls were included in this meta-analysis. In a combined analysis, significantly increased HCC risks were found for null genotype of GSTM1 (OR = 1.29, 95% CI: 1.06-1.58; P = 0.01) and GSTT1 (OR = 1.43, 95% CI: 1.22-1.68; P<10(-5)). Potential sources of heterogeneity were explored by subgroup analysis and meta-regression. Significant results were found in East Asians and Indians when stratified by ethnicity; whereas no significant associations were found among Caucasians and African populations. By pooling data from 12 studies that considered combinations of GSTT1 and GSTM1 null genotypes, a statistically significant increased risk for HCC (OR = 1.88, 95% CI: 1.41-2.50; P<10(-4)) was detected for individuals with combined deletion mutations in both genes compared with positive genotypes.
CONCLUSIONS/SIGNIFICANCE: This meta-analysis suggests that the GSTM1 and GSTT1 null genotype may slightly increase the risk of HCC and that interaction between unfavourable GSTs genotypes may exist.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23185284      PMCID: PMC3502401          DOI: 10.1371/journal.pone.0048924

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related death worldwide [1]. The etiologic importance of chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in HCC has been well established [2], [3]. Not only is HCC an inevitable consequence of chronic HBV or HCV infection, but also other HCC risk factors, such as tobacco smoking, alcohol drinking and aflatoxin exposure, are related to susceptibility to HCC [4], [5]. However, only a minority of patients at risk develops HCC and it is likely that other risk factors such as environmental carcinogenic compounds may contribute to HCC development. This has maintained interest in other biochemical and genetic factors that might contribute to the underlying pathophysiology of HCC. The glutathione S-transferases (GSTs) are a gene superfamily of phase II metabolic enzymes that detoxify free radicals, particularly in tobacco smoke, products of oxidative stress, and carcinogens such as benzopyrene and other polycyclic aromatic hydrocarbons. The most potent mutagenic and carcinogenic of the aflatoxins is aflatoxins B1 (AFB1) which is mainly metabolized by cytochrome P450 3A4 into the genotoxic metabolite AFB1–8,9-exo-epoxide. This metabolite can bind to DNA, causing G-to-T transversions [6] that may ultimately lead to cancer. Detoxification prevents formation of DNA adducts; the metabolite may be conjugated to glutathione by GSTs or may be hydrolyzed. In addition to their role in phase II detoxification, GSTs also play an important role in modulating the induction of other enzymes and proteins for cellular functions, such as DNA repair [7]. GSTM1 and GSTT1 are the most extensively studied genes in the GST gene superfamily. Polymorphic deletion variants in the GSTM1 and GSTT1 genes produce either a functional enzyme (non-deletion alleles or heterozygous deletion, GSTM1-1 and GSTT1-1) or result in the complete absence of the enzyme (homozygous deletion alleles, GSTM1-null and GSTT1-null) [8]. Therefore, these enzymes may be related to the risk for HCC. Over the past few years, considerable efforts have been devoted to exploring the relationships between the GSTT1 and GSTM1 null polymorphisms and HCC risk among various populations. However, existing studies have yielded inconsistent results. These disparate findings may be due partly to insufficient power, false-positive results and publication biases. The interpretation of these studies has been further complicated by the use of different control source. In addition, with the increased studies in recent years among Asian, Caucasian, and other populations, there is a need to reconcile these data. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between GSTM1, GSTT1 and HCC.

Materials and Methods

Literature Search Strategy and Selection Criteria

Genetic association studies published before the end of June 2012 on HCC and polymorphisms in the GST gene were identified through a search of PubMed, Web of Science, EMBASE and CNKI (Chinese National Knowledge Infrastructure). Search term were keywords relating to the relevant gene (e.g. ‘glutathione S-transferase’, ‘GST’, GSTM1’, GSTT1’) in combination with words related to liver cancer (e.g. ‘Hepatocellular carcinoma’, ‘Liver neoplasm’, ‘Liver cancer’) and polymorphism or variation. Furthermore, reference lists of main reports and review articles were also reviewed by a manual search to identify additional relevant publications. The included studies have to meet the following criteria: (1) original papers containing independent data, (2) identification of HCC patients was confirmed histologically or pathologically, (3) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and P-value, (4) case–control or cohort studies. The major reasons for exclusion of studies were (1) overlapping data and (2) case-only studies, family based studies, and review articles.

Eligible Studies and Data Extraction

Data extraction was performed independently by two reviewers and differences were resolved by further discussion among all authors. For each included study, the following information was extracted from each report according to a fixed protocol: first author, publication year, definition and numbers of cases and controls, diagnostic criterion, frequency of genotypes, age, sex, cigarette smoking status, alcohol drinking, ethnicity and genotyping method.

Statistical Methods

For the GSTM1 and GSTT1 gene, we estimated the risks of the null genotype on HCC, compared with the non-null genotypes in the recessive model. The strength of the association between the GSTM1 and GSTT1 gene and HCC risk was measured by odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity across individual studies was calculated using the Cochran chi-square Q test followed by subsidiary analysis or by random-effects regression models with restricted maximum likelihood estimation [9], [10]. Random-effects and fixed-effect summary measures were calculated as inverse variance-weighted average of the log OR. The results of random-effects summary were reported in the text because it takes into account the variation between studies. In addition, sources of heterogeneity were investigated by stratified meta-analyses based on ethnicity, source of controls (population or hospital based) and sample size (No. cases ≥200 or <200). Ethnic group was defined as East Asians, Caucasians (i.e. people of European origin), Indians and Africans. 95% CIs were constructed using Woolf’s method [11]. The significance of the overall OR was determined by the Z-test. Ethnicity, sample size, control source, sex distribution among cases and controls were analyzed as covariates in meta-regression. Funnel plots and Egger’s linear regression test were used to assess evidence for potential publication bias [12]. In order to assess the stability of the result, sensitivity analyses were performed, each study in turn was removed from the total, and the remaining were reanalyzed. All statistical analyses were carried out with the Stata software version 10.0 (Stata Corporation, College Station, TX, USA). The type I error rate was set at 0.05 for two-sided analysis.

Results

Characteristics of Studies

The combined search yielded 287 references. 254 articles were excluded because they clearly did not meet the criteria or overlapping references (Figure S1). Finally, a total of 34 studies were retrieved based on the search criteria for HCC susceptibility related to the GST polymorphisms [13]–[46]. Study quality was assessed according to the score scale for randomized controlled association study proposed by Clark et al [47]. The main study characteristics were summarized in Table 1. There are 33 studies with 4412 cases and 6804 controls concerning GSTM1 and 28 studies with 3892 HCC cases and 6117 controls concerning GSTT1. Of the cases, 74% were East Asians, 10% were Caucasians, 9% were Indians and 7% were African.
Table 1

Characteristics of the studies included in the meta-analysis.

StudyYearEthnicityNo. of casesNo. of controlsSource ofcontrolSex incases(male%)Sex in controls (male%)GenotypingmethodQuality score
Dong [13] 1997Chinese110112Population83.084.7PCR7
Yu [14] 1999Chinese84375Population100100PCR5
Wu [15] 2000Chinese54136Population85.2NAPCR8
Huang [16] 2000Chinese83107PopulationNANAPCR7
Zhu [17] 2001Chinese52100PopulationNANAMD-PCR8
Sun [18] 2001Chinese69128Population83.581.9PCR6
Tiemersma [19] 2001Sudanese112194Population76.875.3Multiplex PCR7
Liu [20] 2002Chinese84144PopulationNANAMultiplex PCR8
Chen [21] 2002Chinese10135Hospital91.348.6PCR5
Munaka [22] 2003Japanese77138Hospital78.268.1PCR10
Wu [23] 2003Chinese6258PopulationNANAPCR6
Liu [24] 2003Chinese5153Hospital86.377.3PCR8
Yu [25] 2003Chinese577389Population86.086.0PCR9
McGlynn [26] 2003Chinese231256Population80.973.8PCR9
Li [27] 2004Chinese207207Population81.681.6PCR8
Deng [28] 2005Chinese181360Hospital80.1NAPCR8
Covolo [29] 2005Italian200400HospitalNANAMultiplex PCR9
Zhu [30] 2005Chinese91130Population86.887.3Multiplex PCR7
Ma [31] 2005Chinese6273Population69.369.9PCR7
Kirk [32] 2005Gambian194352Hospital80.171.6Multiplex PCR8
Long [33] 2005Chinese140536Hospital79.371.6Multiplex PCR9
Zhang [34] 2005Chinese6073Population76.776.7PCR5
Guo [35] 2005Chinese95103Population74.767.0Multiplex PCR8
Ladero [36] 2006Spanish184329Population81.560.2PCR9
Long [37] 2006Chinese257649Hospital80.975.5PCR8
Borentain [38] 2007French5679Population87.567.5PCR10
Kiran [39] 2008Indian63169Hospital90.572.2Duplex PCR7
He [40] 2008Chinese105151Population91.490.7PCR6
Moneim [41] 2008Egyptian6050HospitalNANAPCR8
Imaizumi [42] 2009Japanese209256Hospital67.565.2PCR9
Yang [43] 2009Chinese10060Hospital84.078.3Multiplex PCR5
Asim [44] 2010Indian254525Hospital79.570.7PCR7
Xiao [45] 2011Chinese13075PopulationNANAMultiplex PCR8
Sarma [46] 2012Indian6855Hospital83.858.2PCR7

NA: not available.

NA: not available.

Association of GSTM1null Polymorphism with HCC

Overall, there was evidence of an association between the increased risk of HCC and the null genotype of GSTM1 when all eligible studies were pooled into the meta-analysis. Using random effect model, the summary OR of GSTM1 null genotype was 1.29 (95% CI: 1.06–1.58, P = 0.01, Figure 1) with statistically significant between-study heterogeneity (P<10−5). This analysis is based on pooling of data from a number of different ethnic populations. When stratifying for ethnicity, significant associations were found for East Asians and Indians with OR of 1.28 (95% CI: 1.02–1.61, P = 0.03) and of 2.45 (95% CI: 1.25–4.79, P = 0.009), respectively. Subsidiary analyses of control source yielded an OR for hospital-based controls of 1.44 (95% CI: 1.02–2.02) and for population-based controls of 1.19 (95% CI: 0.95–1.50). When studies were stratified for sample size, significant risk was found in small studies with OR of 1.30 (95% CI: 1.04–1.62, P = 0.02). However, no significant association was detected among seven large studies (Table 2). In meta-regression analysis, ethnicity (P = 0.63), sample size (P = 0.29), source of controls (P = 0.45), sex distribution in cases (P = 0.27) and controls (P = 0.47) did not significantly explained such heterogeneity.
Figure 1

Meta-analysis of GSTM1 null genotype associated with HCC.

Table 2

Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.

Sub-group analysisGSTM1GSTT1
No. ofcase/controlOR (95%CI)P(Z)P(Q)No. ofcase/controlOR (95%CI)P(Z)P(Q)
Overall4412/68041.29 (1.06–1.58)0.01<10−5 3892/61171.43 (1.22–1.68)<10−5 <10−5
Ethnicity
East Asian3221/46511.28 (1.02–1.61)0.03<10−4 2869/42371.40 (1.18–1.66)<10−4 <10−5
Caucasian440/8080.79 (0.50–1.24)0.310.04384/7291.09 (0.71–1.68)0.680.16
Indian385/7492.45 (1.25–4.79)0.0090.02385/7491.96 (0.96–3.98)0.060.01
African366/5961.21 (0.80–1.81)0.370.16254/4021.54 (0.72–3.31)0.270.08
Sample size
<2002477/41221.30 (1.04–1.62)0.02<10−4 2166/36911.48 (1.24–1.75)<10−5 0.002
≥2001935/26821.26 (0.80–2.00)0.32<10−4 1726/24261.30 (0.89–1.91)0.17<10−4
Control source
Hospital2527/25411.44 (1.02–2.02)0.04<10−4 1645/33471.66 (1.30–2.12)<10−5 <10−4
Poulation2508/32191.19 (0.95–1.50)0.13<10−4 2247/27701.28 (1.05–1.55)0.010.002

Association of GSTT1null Polymorphism with HCC

Significant heterogeneity was present among the 28 studies (P<10−5). In a meta-regression analysis, ethnicity (P = 0.53), sample size (P = 0.32), source of controls (P = 0.14), and gender distribution among cases (P = 0.30) and controls (P = 0.38) explained little heterogeneity. Overall, significantly increased HCC risk was found for GSTT1 null genotype (OR = 1.43, 95% CI: 1.22–1.68, P<10−5; Figure 2).
Figure 2

Meta-analysis of GSTT1 null genotype associated with HCC.

In the subgroup analyses by ethnicity, significant risks were found among East Asians with OR of 1.40 (95% CI: 1.18–1.66, P<10−4). However, no such associations were detected among Caucasians, African and Indian populations (Table 2). Subsidiary analyses of sample size yielded an OR for small studies of 1.48 (95% CI: 1.24–1.75, P<10−5), while no significant results were found for large studies. By considering control source subgroups, the OR was 1.28 (95% CI: 1.05–1.55, P = 0.01) in population-based controls, compared to 1.66 (95% CI: 1.30–2.12, P<10−5) in hospital controls.

Gene–gene Interaction

The effect of each genotype of GSTs was independently assessed. Significant association was established between the null genotype of GSTM1, GSTT1 and HCC. The data on both null genotype of GSTs among cases and controls were available in 12 studies which included 1762 cases and 2443 controls. The interaction between GSTM1 null and GSTT1 null, for which an OR of 1.88 (95% CI: 1.41–2.50, P<10−4; figure3) for HCC appeared in compared with individuals with the positive genotypes.

Sensitivity Analyses and Publication Bias

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual data-set to the pooled ORs, and the corresponding pooled ORs were not qualitatively altered. Begg’s funnel plot and Egger’s test were performed to access the publication bias of the literatures. The shape of the funnel plots was symmetrical for these polymorphisms (Figure S2 and S3). The statistical results still did not show publication bias in these studies for GSTM1 (Egger test, P = 0.90) and GSTT1 (Egger test, P = 0.55).

Discussion

Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and diseases. This is the most comprehensive meta-analysis that examined the GSTM1, GSTT1 null polymorphism and the relationship to susceptibility for hepatocellular carcinoma. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 34 studies for hepatocellular carcinoma, which provided 4463 cases and 6857 controls. Our results demonstrated that the GSTM1 and GSTT1 null polymorphism is a risk factor for developing hepatocellular carcinoma. However, this association became non-significant when the meta-analysis was restricted to larger studies, suggesting potential small studies effects. In the stratified analysis by ethnicity, significant associations were found in East Asians for the two polymorphisms. Significant result was also found among Indians for GSTT1 null polymorphism. However, no significant associations were detected among Caucasian and African populations for the two polymorphisms. There are several possible reasons for such differences. Firstly, the frequencies of the risk-association homozygous null genotype vary between different races. For example, the homozygous null genotype distributions of the GSTT1 polymorphism varies between East Asian, Indian and African populations, with a prevalence of ∼52%, ∼29%, and ∼31%, respectively [19], [22], [39]. Therefore, additional studies are warranted to further validate ethnic difference in the effect of these polymorphisms on HCC risk. Secondly, such different results could also be explained by study design or sample size. Besides, other confounding factors, such as age, sex, life style should also be considered. Thus, further prospective researches are needed to examine the effect of this variation on HCC to make a comprehensive and true conclusion [18]. Other confounding factors, such as age, life style (e.g. smoking, alcohol consumption) should also be considered [22], [27], [36]. Nevertheless, owing to the limited number of relevant studies among Caucasians and Africans included in this meta-analysis, the observed ethnic difference in this meta-analysis is also likely to be caused by chance because studies with small sample sizes may have insufficient statistical power to detect a slight effect or may have generated a fluctuated risk estimate. Thus, further studies including a wider spectrum of subjects to investigate the role of this variant in these populations will be needed. Our results indicated that significantly increased HCC risk in GSTM1 null genotype was found among the hospital-based studies but not in population-based studies. Possible reason could be that the hospital-based studies have some biases because such controls may just represent a sample of ill-defined reference population, and may not be representative of the general population very well, particularly when the genotypes under investigation were associated with the disease conditions that the hospital-based controls may have. Therefore, using a proper and representative population-based control subjects is very important to reduce biases in such genetic association studies. If genetic susceptibility to HCC is, in part, mediated through metabolic gene polymorphisms, it is possible that the combinations of certain genotypes may be more discriminating as risk factors for HCC than a single locus genotype. Among the 34 studies included in the present meta-analysis, 12 studies investigated the interaction between GSTM1 and GSTT1 polymorphism. By pooling the collected data on GSTM1 and GSTT1 genotypes, a statistically significant 1.88-fold increased risk for HCC appeared for individuals with combined deletion mutations in GSTT1 and GSTM1 genes in comparison with individuals with the positive genotypes. This result suggests that in the presence of both of the two risk factors, an important number of HCC cases would occur. It is well accepted that the strength of an association is not an inherent biologic property with small associations potentially reflecting important causal relations. It may take relatively few common genetic variants, each conveying only small to modest excess risk, to account for a sizable portion of the population attributable fraction for common diseases (e.g., 10–18 genes, each with a 20–30 percent prevalence and conveying an odds ratio of only 1.2–1.5 to explain between 30 and 50 percent of the population attributable fraction [48]. Recently, several other drug metabolizing genes were found to be associated with HCC susceptibility. N-acetyltransferase 2 and CYP1A1 genotype were found to be associated with increased risk of HCC among smokers [49], [50]. Liu et al. reported that CYP2E1 PstI/RsaI polymorphism was significantly associated with increased HCC susceptibility among alcohol drinkers [51]. Therefore, these gene/polymorphisms which works in close network with each other should be address in future studies. A number of factors predict HCC, however, detailed pathogenesis mechanisms of HCC remain a matter of speculation. Members of the GST family are important candidates for involvement in susceptibility to commonly occurring forms of cancer, because they may regulate an individual’s ability to metabolize environmental carcinogens [52]. Normal or increased GST enzyme activity or levels may protect susceptible tissues from somatic mutations in DNA by facilitating the conjugation and subsequent elimination of electrophilic carcinogens [53]. Absent or deficient GST enzyme activity may result in poorer elimination of electrophilic carcinogens, particularly in the presence of very active electrophilic activation by phase I enzymes. If an individual’s inherited genotype at a GST locus does not permit the efficient metabolism of compounds involved in carcinogens, then that individual may be at increased cancer risk. GSTM1 and GSTT1 are two important members of GSTs supergene family, which plays an important role in the second stage of biotransformation by conjugating extraneous chemicals with glutathione [54]. Previous some studies have showed that the deficient types of GSTM1 and GSTT1, namely GSTM1-null and GSTT1-null genotypes are completely lack of respective enzyme activity and cannot metabolize transfer AFB1-epoxide, the most important metabolic carcinogen of AFB1, to un-toxic metabolite which is highly soluble and can be excreted out of body, which may be associated with the increased risk of HCC [18], [32]. Compared with the previous meta-analysis [55]–[57], the present study is much larger. In addition, we assessed not only the effect of each genotype of GSTs and HCC independently but also the interaction effect between GSTM1 and GSTT1. Furthermore, we also performed meta-regression to evaluate the effect of several preselected factors on the observed variability among studies evaluating GSTM1 or GSTT1 null genotype. Our results suggest an overestimation of the true genetic association by small studies, consistent with the phenomenon known as “winner’s curse” [58], [59]. In interpreting the results, some limitations of this meta-analysis should be addressed. Firstly, heterogeneity is a potential problem when interpreting all the results of meta-analysis. Although we minimized the likelihood by performing a careful search for published studies, using the explicit criteria for study inclusion, the significant between-study heterogeneity still existed in most of comparison. The presence of heterogeneity can result from differences in the age distribution, selection of controls, prevalence lifestyle factors and so on. Secondly, the subgroup meta-analyses considering interactions between GSTM1, GSTT1 null genotype and ethnic difference, as well as between GSTT1 null and GSTM1 null genotypes, were performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be over inflated. In this context, more reliable results can be expected if individual data are available for a pooled analysis. Finally, lacking the original data of the reviewed studies limited our further evaluation of potential interactions because the interactions between gene-environment, such aflatoxin B1 exposure, HBV or HCV infection, smoking and alcohol abuse. Despite these limitations, this meta-analysis suggests that the null genotypes of GSTM1 and GSTT1 may increase the risk of HCC, particularly in East Asian population. In addition, the combination of unfavourable genotypes of GSTM1 and GSTT1 may result in an additional risk of HCC. For future association studies, strict selection of patients and controls, larger studies of different ethnic populations will be required. Moreover, gene–gene and gene–environment interactions should also be considered in future studies. Flow diagram of the study selection process. (TIF) Click here for additional data file. Begg’s funnel plot for publication bias in selection of studies on GSTM1 polymorphism. (TIF) Click here for additional data file. Begg’s funnel plot for publication bias in selection of studies on GSTT1 polymorphism. (TIF) Click here for additional data file. (DOC) Click here for additional data file.
  43 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma.

Authors:  E W Tiemersma; R E Omer; A Bunschoten; P van't Veer; F J Kok; M O Idris; A M Kadaru; S S Fedail; E Kampman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-07       Impact factor: 4.254

3.  GST polymorphisms are associated with hepatocellular carcinoma risk in Chinese population.

Authors:  Lei Yu; Chun-Yu Wang; Bo Xi; Lei Sun; Ruo-Qi Wang; Yin-Kun Yan; Li-Ying Zhu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

4.  Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis.

Authors:  Bin Wang; Gang Huang; Dan Wang; Aijun Li; Zhipeng Xu; Ran Dong; Deqiang Zhang; Weiping Zhou
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

5.  Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls.

Authors:  Shu-Yuan Chen; Li-Yu Wang; Ruth M Lunn; Wei-Yann Tsai; Po-Huang Lee; Chue-Shue Lee; Habibul Ahsan; Yu-Jing Zhang; Chien-Jen Chen; Regina M Santella
Journal:  Int J Cancer       Date:  2002-05-01       Impact factor: 7.396

6.  Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma.

Authors:  Ming-Whei Yu; Shi-Yi Yang; I-Jen Pan; Chih-Lin Lin; Chun-Jen Liu; Yun-Fan Liaw; Shi-Ming Lin; Pei-Jer Chen; Shou-Dong Lee; Chien-Jen Chen
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

7.  Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India.

Authors:  Manjula Kiran; Yogesh Kumar Chawla; Jyotdeep Kaur
Journal:  DNA Cell Biol       Date:  2008-12       Impact factor: 3.311

8.  Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma.

Authors:  Masahiro Munaka; Kiyotaka Kohshi; Toshihiro Kawamoto; Shin Takasawa; Naoki Nagata; Hideaki Itoh; Susumu Oda; Takahiko Katoh
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-21       Impact factor: 4.553

9.  Hepatitis C virus related hepatocellular carcinoma: a case control study from India.

Authors:  Manash Pratim Sarma; Mohammad Asim; Subhash Medhi; Thayumanavan Bharathi; Premashis Kar
Journal:  J Med Virol       Date:  2012-07       Impact factor: 2.327

10.  Overestimation of genetic risks owing to small sample sizes in cardiovascular studies.

Authors:  T M Morgan; C S Coffey; H M Krumholz
Journal:  Clin Genet       Date:  2003-07       Impact factor: 4.438

View more
  19 in total

Review 1.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

2.  Glutathione-s-transferase A 4 (GSTA4) suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting AKT pathway.

Authors:  Chang Jun Liu; Jin Hui Yang; Fei Zhou Huang; Wan Pin Nie; Chu Ping Liu; Xian Hai Mao; Xin Min Yin; Xian Bo Shen; Chuang Peng; Mei Fu Chen; Bo Jiang; Xun Yang Liu; Jin Shu Wu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  Age- and gender-independent association of glutathione S-transferase null polymorphisms with chronic myeloid leukemia.

Authors:  Abdel Rahim Mahmoud Muddathir; Elharam Ibrahim Abdallah; Omar Falah Khabour; Ream Elzain Abdelgader; Mahmoud Mohamed Elgari
Journal:  Bosn J Basic Med Sci       Date:  2019-04-15       Impact factor: 3.363

4.  GSTM1 null genotype is a risk factor for laryngeal cancer.

Authors:  Xuejun Liu; Qijun Fan; Liyan Ni; Fanli Liu; Saiyu Huang; Jinjian Gao; Bobei Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Gene-gene and gene-environment interactions in meta-analysis of genetic association studies.

Authors:  Chin Lin; Chi-Ming Chu; John Lin; Hsin-Yi Yang; Sui-Lung Su
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

Review 6.  GSTT1 and GSTM1 polymorphisms and prostate cancer risk in Asians: a systematic review and meta-analysis.

Authors:  Dajun Liu; Ying Liu; Limei Ran; Huiping Shang; Detian Li
Journal:  Tumour Biol       Date:  2013-06-28

7.  Genetic polymorphisms in Glutathione S-transferase Omega (GSTO) and cancer risk: a meta-analysis of 20 studies.

Authors:  You-Tao Xu; Jun Wang; Rong Yin; Man-Tang Qiu; Lei Xu; Jie Wang; Lin Xu
Journal:  Sci Rep       Date:  2014-10-10       Impact factor: 4.379

Review 8.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

9.  The effect of CYP, GST, and SULT polymorphisms and their interaction with smoking on the risk of hepatocellular carcinoma.

Authors:  Stefania Boccia; Luca Miele; Nikola Panic; Federica Turati; Dario Arzani; Consuelo Cefalo; Rosarita Amore; Milutin Bulajic; Maurizio Pompili; Gianlodovico Rapaccini; Antonio Gasbarrini; Carlo La Vecchia; Antonio Grieco
Journal:  Biomed Res Int       Date:  2015-01-14       Impact factor: 3.411

10.  Bone marrow injury induced via oxidative stress in mice by inhalation exposure to formaldehyde.

Authors:  Yuchao Zhang; Xudong Liu; Cliona McHale; Rui Li; Luoping Zhang; Yang Wu; Xin Ye; Xu Yang; Shumao Ding
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.